跳至主要内容
临床试验/NCT01799863
NCT01799863已完成2 期

Artificial Tears Versus Preservative Free Ketorolac Trometamol 0.45% for Treatment of Acute Viral Conjunctivitis

Fundação Altino Ventura1 个研究点 分布在 1 个国家目标入组 50 人开始时间: 2012年6月最近更新:
适应症
干预措施
相关药物

试验速览

阶段
2 期
状态
已完成
发起方
入组人数
50
试验地点
1
主要终点
Change in ocular symptoms from baseline to treatment day 7

研究概览

简要总结

The purpose of this study is to evaluate the evolution of the symptoms of acute viral conjunctivitis using preservative free ketorolac trometamol 0.45% associated with carboxymethylcellulose compared with isolated use of preservative-free artificial tears.

详细描述

The purpose of this study is to evaluate the evolution of the symptoms of acute viral conjunctivitis using preservative free ketorolac trometamol 0.45% associated with carboxymethylcellulose compared with isolated use of preservative-free artificial tears. A randomized double-masked study will include 60 patients divided into two groups: Group 1: using a formulation of ketorolac tromethamine 0.45% associated with carboxymethylcellulose (Acular CMC®, Allergan, Irvine, USA) and Group 0: using artificial tears (Optive UD®, Allergan, Irvine, USA), both drugs without preservatives.

研究设计

研究类型
Interventional
分配方式
Randomized
干预模型
Parallel
主要目的
Treatment
盲法
Triple (Participant, Care Provider, Investigator)

入排标准

年龄范围
18 Years 至 70 Years(Adult, Older Adult)
性别
All
接受健康志愿者

入选标准

  • Acute conjunctivitis (unilateral or bilateral) for less than two weeks,
  • Signs and symptoms consistent with viral conjunctivitis and at least one of the following: preauricular lymphadenopathy, upper tract respiratory infection or recent contact with someone with conjunctivitis

排除标准

  • pregnant women
  • allergies to non-steroidal anti-inflammatories
  • history of seasonal allergic conjunctivitis
  • contact lens wearers
  • history of ocular herpes infection
  • blepharitis
  • severe dry eye
  • purulent discharge
  • defects in the corneal epithelium

研究组 & 干预措施

Ketorolac trometamol 0.45%

Experimental

Ketorolac trometamol 0.45% associated with carboxymethylcellulose eye drops (Acular CMC®, Allergan, Irvine, USA) qid for 7 days.

干预措施: Ketorolac trometamol 0.45% with carboxymethylcellulose (Drug)

Artificial tears

Placebo Comparator

Preservative free artificial tears (Optive UD®, Allergan, Irvine, USA) qid for 7 days.

干预措施: Preservative free artificial tear (Drug)

结局指标

主要结局

Change in ocular symptoms from baseline to treatment day 7

时间窗: 7 days

General ocular discomfort, itching, foreign body sensation, tearing, eye redness and eyelid edema. Symptoms will be graded as 0 (absence), I (mild), II (moderate) and III (severe).

Change in ocular signs from baseline to treatment day 7

时间窗: 7 days

The clinical examination will consist of slit-lamp examination of the anterior segment. Four signs will be assessed: conjunctival hyperemia, chemosis, secretion and follicles in lower tarsal conjunctiva. The signs will be classified as 0 (absence), I (mild), II (moderate), III (severe)

次要结局

未报告次要终点

研究者

发起方
Fundação Altino Ventura
申办方类型
Other
责任方
Sponsor

研究点 (1)

Loading locations...

相似试验

Artificial Tears Versus Preservative Free Ketorolac... | 临床试验